Northwestern Mutual Wealth Management Co. Has $19.68 Million Position in Stryker Corporation $SYK

Key Points

• Northwestern Mutual Wealth Management Co. increased its stake in Stryker Corporation by 5.4%, raising its holdings to 52,856 shares valued at approximately $19.68 million.
• Stryker reported impressive earnings, with $3.13 EPS for the quarter, exceeding estimates, and revenue reaching $6.02 billion, representing an 11.1% year-over-year increase.
• The company declared a quarterly dividend of $0.84, amounting to an annualized yield of 0.9%, with a payout ratio of 44.50%.

Northwestern Mutual Wealth Management Co. boosted its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 5.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,856 shares of the medical technology company's stock after acquiring an additional 2,713 shares during the period. Northwestern Mutual Wealth Management Co.'s holdings in Stryker were worth $19,676,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Capital A Wealth Management LLC acquired a new position in shares of Stryker during the fourth quarter valued at about $26,000. Goodman Advisory Group LLC acquired a new position in shares of Stryker during the first quarter valued at about $32,000. City Holding Co. raised its position in shares of Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after buying an additional 74 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker during the first quarter valued at about $40,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Stryker during the fourth quarter valued at about $42,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Activity at Stryker

In other news, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company's stock, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Price Performance

Stryker stock traded up $1.81 during trading hours on Friday, hitting $391.48. 672,496 shares of the stock were exchanged, compared to its average volume of 1,416,819. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The stock has a market capitalization of $149.67 billion, a P/E ratio of 51.85, a P/E/G ratio of 2.86 and a beta of 0.91. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The business's 50-day moving average is $388.94 and its two-hundred day moving average is $379.43.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. During the same period in the prior year, the firm earned $2.81 earnings per share. The company's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's dividend payout ratio is 44.50%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SYK. Roth Mkm upped their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Truist Financial set a $415.00 price target on shares of Stryker and gave the stock a "hold" rating in a research report on Monday, August 4th. JMP Securities reissued a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Evercore ISI increased their price target on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Finally, BTIG Research reissued a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $430.10.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.